
Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, and streamline analytics.
With over 25 years of experience in the pharma services industry, I currently lead Veristat as Chief Executive Officer, driving global clinical operations with a focus on strategic planning, operational excellence, and scientific expertise. My mission is to deliver high-quality solutions that empower sponsors to successfully execute their clinical development programs. I am committed to ensuring consistent performance and fostering client trust while enhancing operational efficiency and profitability. Previously, as Chief Operating Officer at Veristat and THREAD, I spearheaded the planning, implementation, and management of operational strategies for clinical research and decentralized clinical trial platforms. Collaborating closely with teams and clients, I enabled the delivery of innovative drug development programs while optimizing resource utilization and restructuring operations to improve profitability. My pragmatic leadership style is rooted in building and transforming organizations to maximize value and drive impactful results.

Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, and streamline analytics.

Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.

Kim Boericke, CEO, Veristat, notes that advancing women into STEM leadership requires strong advocacy from senior leaders, strategic career planning, and building visibility through cross-functional collaboration and networking.